| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $2,433,286 | 14 | 100 |
| Wilson Mark Andrew | Chief Legal Officer | 0 | $0 | 1 | $34,196 | $-34,196 |
| Zalevsky Jonathan | Chief R&D Officer | 0 | $0 | 7 | $974,185 | $-974,185 |
| ROBIN HOWARD W | President & CEO | 0 | $0 | 6 | $1.42M | $-1.42M |
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung …
Over the last 12 months, insiders at Nektar Therapeutics have bought $0 and sold $2.43M worth of Nektar Therapeutics stock.
On average, over the past 5 years, insiders at Nektar Therapeutics have bought $0 and sold $1.43M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 15,000 shares for transaction amount of $259,200 was made by Doberstein Stephen K (SVP & Chief Scientific Officer) on 2019‑09‑05.
| 2026-08-18 | Sale | ROBIN HOWARD W | President & CEO | 418 0.0014% | $71.98 | $30,088 | -19.46% | |
| 2026-08-18 | Sale | Zalevsky Jonathan | Chief R&D Officer | 186 0.0006% | $71.98 | $13,388 | -19.46% | |
| 2026-06-30 | Sale | Zalevsky Jonathan | Chief R&D Officer | 5,681 0.0292% | $70.00 | $397,670 | -1.75% | |
| 2026-06-17 | Sale | ROBIN HOWARD W | President & CEO | 10,000 0.0514% | $61.19 | $611,880 | +12.13% | |
| 2026-06-16 | Sale | ROBIN HOWARD W | President & CEO | 10,000 0.0512% | $60.32 | $603,176 | +13.32% | |
| 2026-06-15 | Sale | Zalevsky Jonathan | Chief R&D Officer | 5,538 0.0281% | $60.71 | $336,212 | +11.66% | |
| 2026-05-19 | Sale | ROBIN HOWARD W | President & CEO | 444 0.0022% | $65.51 | $29,086 | -1.35% | |
| 2026-05-19 | Sale | Zalevsky Jonathan | Chief R&D Officer | 199 0.001% | $65.51 | $13,036 | -1.35% | |
| 2026-02-18 | Sale | ROBIN HOWARD W | President & CEO | 423 0.0021% | $73.00 | $30,879 | -3.54% | |
| 2026-02-18 | Sale | Zalevsky Jonathan | Chief R&D Officer | 180 0.0009% | $73.00 | $13,140 | -3.54% | |
| 2026-01-20 | Sale | Zalevsky Jonathan | Chief R&D Officer | 3,867 0.0187% | $35.67 | $137,936 | +91.80% | |
| 2025-11-25 | Sale | ROBIN HOWARD W | President & CEO | 2,207 0.0108% | $54.28 | $119,796 | +11.65% | |
| 2025-11-25 | Sale | Wilson Mark Andrew | Chief Legal Officer | 630 0.0031% | $54.28 | $34,196 | +11.65% | |
| 2025-11-25 | Sale | Zalevsky Jonathan | Chief R&D Officer | 1,157 0.0057% | $54.28 | $62,802 | +11.65% | |
| 2025-09-09 | Sale | ROBIN HOWARD W | President & CEO | 6,666 0.0337% | $46.69 | $311,214 | +34.26% | |
| 2025-09-05 | Sale | ROBIN HOWARD W | President & CEO | 6,666 0.0336% | $38.53 | $256,851 | +61.60% | |
| 2025-09-04 | Sale | ROBIN HOWARD W | President & CEO | 5,166 0.0254% | $33.70 | $174,108 | +80.39% | |
| 2025-09-04 | Sale | Zalevsky Jonathan | Chief R&D Officer | 1,721 0.0084% | $33.52 | $57,693 | +80.39% | |
| 2025-09-02 | Sale | ROBIN HOWARD W | President & CEO | 1,500 0.0082% | $30.16 | $45,240 | +122.89% | |
| 2025-09-02 | Sale | Zalevsky Jonathan | Chief R&D Officer | 485 0.0026% | $30.10 | $14,599 | +122.89% |
| ROBIN HOWARD W | President & CEO | 54627 0.1904% | $2.06M | 1 | 92 | <0.0001% |
| WHITFIELD ROY A | director | 216250 0.7538% | $8.17M | 3 | 2 | +51.06% |
| GREER R SCOTT | director | 176574 0.6155% | $6.67M | 1 | 5 | +42.48% |
| Doberstein Stephen K | SVP & Chief Scientific Officer | 107668 0.3753% | $4.07M | 1 | 20 | +17.27% |
| WINGER DENNIS L | director | 42750 0.149% | $1.61M | 1 | 4 | +8.33% |
| DRAPEAU LOUIS | Sr. VP Finance, CFO | 5000 0.0174% | $188,800.00 | 5 | 0 | <0.0001% |
$831,902,292 | 108 | 9.34% | $1.2B | |
$15,410,062 | 81 | 39.69% | $975.93M | |
$11,663,618 | 57 | 32.20% | $934.29M | |
$24,007,605 | 16 | -20.65% | $1.33B | |
$50,366,509 | 15 | 36.17% | $967.96M |
| Increased Positions | 114 | +62.64% | 7M | +47.65% |
| Decreased Positions | 77 | -42.31% | 4M | -26.52% |
| New Positions | 64 | New | 3M | New |
| Sold Out Positions | 34 | Sold Out | 1M | Sold Out |
| Total Postitions | 219 | +20.33% | 17M | +21.13% |
| Bvf Inc/Il | $55,430.00 | 6.38% | 1.28M | +1M | New | 2025-09-30 |
| Vanguard Group Inc | $41,190.00 | 4.74% | 948,647 | +219,155 | +30.04% | 2025-09-30 |
| Morgan Stanley | $40,344.00 | 4.65% | 929,151 | +857,012 | +1,188% | 2025-09-30 |
| Susquehanna International Group, Llp | $40,159.00 | 4.62% | 924,896 | +703,005 | +316.82% | 2025-09-30 |
| Farallon Capital Management Llc | $34,345.00 | 3.96% | 791,000 | +791,000 | New | 2025-09-30 |
| Blackrock, Inc. | $26,448.00 | 3.05% | 609,114 | +193,888 | +46.7% | 2025-09-30 |
| Millennium Management Llc | $23,707.00 | 2.73% | 545,994 | -103,039 | -15.88% | 2025-09-30 |
| Two Sigma Investments, Lp | $18,855.00 | 2.17% | 434,237 | +354,842 | +446.93% | 2025-09-30 |
| Nantahala Capital Management, Llc | $18,172.00 | 2.09% | 418,522 | -291,239 | -41.03% | 2025-09-30 |
| Citadel Advisors Llc | $15,678.00 | 1.81% | 361,073 | +361,073 | New | 2025-09-30 |